期刊文献+

蛋白质和多肽药物稳定性研究进展 被引量:3

Research Progress in Drug Stability of Proteins and Polypeptides
下载PDF
导出
摘要 目前,蛋白质和多肽类药物在临床中被广泛应用。与小分子药物相比,蛋白质和多肽类药物具有良好的生物活性,高度专一性以及低毒性,但是其稳定性低,且易被清除,这限制了其药效的最大发挥。本文分析了不同给药方式下影响蛋白质及多肽类药物药效的主要因素,并对提高药物稳定性的方法进行了简介。 At present,protein and polypeptide drugs are widely used in clinic.Compared with small molecule drugs,protein and polypeptide drugs have good biological activity,high specificity and low toxicity,but their stability is low and easy to be eliminated,which limits the maximum play of their efficacy.In this paper,the main factors affecting the drug efficacy of proteins and polypeptides under different administration modes were analyzed,and the methods to improve drug stability were introduced.
作者 杨梦雪 Yang Mengxue(Shihezi No.2 Middle School, Xinjiang, 832000)
机构地区 石河子第二中学
出处 《当代化工研究》 2017年第11期133-134,共2页 Modern Chemical Research
关键词 多肽 蛋白质 药物 稳定性 PEG化 polypeptide protein drugs stability pegylation
  • 相关文献

参考文献3

二级参考文献34

  • 1Elliott S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology, 2004, 32 (12) :1146 - 1155.
  • 2Derek Macmillan. Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin. Chemistry & Biology, 2001,8 (2) :133- 145.
  • 3Sinclair A M, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci, 2005, 94 (8) :1626 - 1635.
  • 4Glaspy J. Phase Ⅲ clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol, 2005, 18 (3) :4O7 -416.
  • 5Dunn C J, Plosker G L, Keating G M, et al. Insulin glargine:an updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63 (16) : 1743 -1778.
  • 6Scholtz H E, Pretorius S G, Wessels D H, et al.Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia,2005, 48(10) : 1988 - 1995.
  • 7Lee G K. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng,2005, 92( 1 ) :24 -34.
  • 8Vemnese F M, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today, 2005,10 (21) : 1451 -1458.
  • 9Talpaz M, Phase I evaluation of a 40kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res,2005, 11 ( 17 ) : 6247 - 2655.
  • 10Robeas M J, Bentley M D, Harris J M. Chemistru for peptide and protein PEGylation. Advanced Drug Delivery Reviews,2002, 54 (4) : 459 -476.

共引文献27

同被引文献31

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部